Articles tagged with Ovarian Cancer
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Researchers have identified a protein complex that drives T cell exhaustion in tumors and show that disrupting it can revive exhausted anti-tumor CTLs. The study's findings offer new hope for improving the efficacy of cancer immunotherapy.
Australian scientists have developed a new blood test that can identify women with ovarian cancer more likely to benefit from PARP inhibitor therapy, offering hope for more effective treatment. The test measures immune biomarkers and predicts which patients will respond to treatment.
MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
A major study of breast, cervical, and ovarian cancers found significant inequalities in global care, with many low- and middle-income countries (LMICs) diagnosing cancer at a later stage. Surgery was offered consistently, but treatment consistency varied, with LMICs often choosing mastectomy over breast-conserving surgery.
Black and Asian patients were underrepresented in clinical trials, leading to worse survival outcomes compared to white counterparts, despite similar progression-free survival rates. Equitable enrollment is crucial for access to cutting-edge treatments and long-term equity in cancer care.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
MSK researchers have developed a new method to study treatment resistance in high-grade serous ovarian cancer. By analyzing blood samples from 18 patients, they identified subpopulations of cancer cells with distinctive genetic features that contribute to recurrence. This approach may help develop targeted treatments for specific vulne...
The loss of Trp53 leads to more aggressive tumor growth and weaker immune responses in ovarian cancer. Researchers developed a mouse model that mimics human HGSC, showing how the disease progresses and evades the immune system.
Researchers identified NBL1 as a key driver of ovarian cancer metastasis through its activation of the Jak/Stat3 pathway. NBL1 expression levels strongly correlated with advanced clinical stage and poor survival outcomes.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
Researchers developed Ovatools, a tool combining blood test results and age to identify women at higher risk of ovarian cancer. The approach is accurate for women over 50 and represents good value for the NHS, detecting more cancers earlier while remaining within affordability thresholds.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
A significant proportion of patients with high-grade serous ovarian cancer missed genetic testing and surgical prevention opportunities due to limited effective screening options and treatment limitations. The study emphasizes the importance of addressing these gaps to eradicate this aggressive form of ovarian cancer.
Researchers identify three tumor-reactive T cell subpopulations that exhibit selective expansion in ovarian cancer patients. CD8+ TCF7-expressing Tpex cells demonstrate self-renewal capacity and generate stem-like progenies, which may enhance persistence and specificity in current TIL therapy.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
A 23-year bibliometric analysis reveals key hotspots in ovarian cancer care, including quality of life, surgery, and nursing health. The study emphasizes the need for future research on psychological well-being and integrated care models to improve outcomes for women with ovarian cancer.
Researchers developed a novel radioimmunotherapy that successfully eliminated cancer stem cells (CSCs) in preclinical models of ovarian cancer. The therapy, targeting CSC-associated biomarkers L1CAM + /CD133 + , showed significantly increased cytotoxicity compared to existing treatments.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
A new study found that over 65% of ovarian cancer tumors exhibit whole-genome doubling, making them more resistant to treatments. WGD-high tumors suppress the immune response by repressing key pathways.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
A retrospective analysis of 22 patients with brain metastases from ovarian cancer treated with Gamma Knife stereotactic radiosurgery (GKSRS) showed a high intracranial tumor control rate of 97.1% at 12 months post-treatment. No acute or chronic toxicity was observed in the study.
A new combination treatment strategy selectively targets ovarian tumor cells, reducing growth in preclinical models. The approach identifies effective regimens to treat genetically diverse cancers by blocking specific growth signaling pathways.
A new genetic marker, PPP2R1A mutations, has been linked to improved survival rates for patients treated with immunotherapy in ovarian and other cancers. Targeting this biomarker may further enhance treatment outcomes, suggesting a potential new therapeutic target.
Researchers employed a novel validation-based insertional mutagenesis technique to identify genes conferring carboplatin resistance in human epithelial ovarian cancer cells. HN1L was found to enhance resistance by activating NF-κB signaling, and targeting this gene may represent a promising strategy for overcoming platinum resistance.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers discovered that blocking PRDX1 protein can make ovarian cancer cells more responsive to DNA-damaging platinum therapies. The study suggests targeting PRDX1 could be a viable strategy to improve chemotherapy efficacy.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
A study found that removing ovaries and fallopian tubes in women with BRCA1 and BRCA2 genetic variants significantly reduces the risk of early death from cancer. This procedure, known as bilateral salpingo-oophorectomy (BSO), also decreases the risk of developing a second cancer without any serious side effects.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
A 'master regulator' gene, ZNFX1, has been identified that may help guide treatment in patients with therapy-resistant ovarian cancer. The expression of this biomarker correlates with improved survival outcomes.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A novel subset of progenitor cells, called high-risk MSCs, reside in the stroma and promote DNA damage and tumor growth. These cells play a critical role in the initiation of ovarian cancer, particularly in older women or those with BRCA mutations.
Researchers found that Black women have nearly identical mutations to other populations but experience lower survival rates due to clinical factors. The study highlights the importance of studying different population groups to improve ovarian cancer healthcare and develop targeted treatments.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Researchers found that women who had used the oral contraceptive pill had a lower risk of ovarian cancer, with a 39% reduced risk for those who had given birth to two or more children. The study also identified certain biomarkers and lifestyle factors associated with a lower risk of ovarian cancer, including lower body weight and short...
A mathematical modeling study suggests that removing fallopian tubes during other abdominal surgeries can lower ovarian cancer incidence by five percent. The approach could also reduce total healthcare costs in Germany, with estimated annual savings of over €10 million.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.